G Levy

415 total citations
8 papers, 333 citations indexed

About

G Levy is a scholar working on Rheumatology, Genetics and Oncology. According to data from OpenAlex, G Levy has authored 8 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Rheumatology, 4 papers in Genetics and 3 papers in Oncology. Recurrent topics in G Levy's work include Osteoarthritis Treatment and Mechanisms (4 papers), Inflammatory Bowel Disease (4 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). G Levy is often cited by papers focused on Osteoarthritis Treatment and Mechanisms (4 papers), Inflammatory Bowel Disease (4 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). G Levy collaborates with scholars based in United States, Canada and Spain. G Levy's co-authors include Roy Fleischmann, Francis Bérenbaum, Jan Paul Medema, Marc C. Levesque, Sheng Feng, Francisco J. Blanco, Thomas J. Schnitzer, Henning Bliddal, Philip G. Conaghan and Jean‐Pierre Pelletier and has published in prestigious journals such as Annals of the Rheumatic Diseases, Arthritis & Rheumatology and Journal of Crohn s and Colitis.

In The Last Decade

G Levy

8 papers receiving 332 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G Levy United States 5 263 119 72 50 46 8 333
Ann Tamm Estonia 9 289 1.1× 101 0.8× 72 1.0× 107 2.1× 36 0.8× 18 350
Irina Kerna Estonia 8 185 0.7× 70 0.6× 87 1.2× 44 0.9× 41 0.9× 12 288
Brendon Richbourgh United States 6 133 0.5× 56 0.5× 136 1.9× 28 0.6× 39 0.8× 7 359
Zrinka Jajić Croatia 10 194 0.7× 32 0.3× 104 1.4× 18 0.4× 69 1.5× 43 339
A. Florescu Denmark 7 174 0.7× 22 0.2× 45 0.6× 39 0.8× 38 0.8× 9 309
J. Ophir Israel 11 111 0.4× 29 0.2× 64 0.9× 32 0.6× 38 0.8× 23 383
M.A. Pest Canada 11 223 0.8× 150 1.3× 174 2.4× 74 1.5× 96 2.1× 18 444
Nigel K. Arden United Kingdom 5 140 0.5× 86 0.7× 87 1.2× 38 0.8× 19 0.4× 5 245
Maria Rosaria Povino Italy 9 178 0.7× 22 0.2× 119 1.7× 33 0.7× 133 2.9× 12 407
Josef Symon S. Concha United States 12 197 0.7× 33 0.3× 35 0.5× 21 0.4× 8 0.2× 25 360

Countries citing papers authored by G Levy

Since Specialization
Citations

This map shows the geographic impact of G Levy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Levy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Levy more than expected).

Fields of papers citing papers by G Levy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G Levy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Levy. The network helps show where G Levy may publish in the future.

Co-authorship network of co-authors of G Levy

This figure shows the co-authorship network connecting the top 25 collaborators of G Levy. A scholar is included among the top collaborators of G Levy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Levy. G Levy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Reinisch, Walter, Kamal Patel, Natalia Borruel, et al.. (2023). P658 Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison. Journal of Crohn s and Colitis. 17(Supplement_1). i785–i786. 2 indexed citations
2.
Panaccione, Remo, Gary Lichtenstein, Alessandro Armuzzi, et al.. (2023). P518 Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE). Journal of Crohn s and Colitis. 17(Supplement_1). i644–i646. 4 indexed citations
3.
Reinisch, Walter, Marjolijn Duijvestein, Daniel Ceballos, et al.. (2023). P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison. Journal of Crohn s and Colitis. 17(Supplement_1). i672–i673. 3 indexed citations
4.
Vermeire, Séverine, Silvio Danese, Wen Zhou, et al.. (2022). DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis. Journal of Crohn s and Colitis. 16(Supplement_1). i090–i091. 11 indexed citations
5.
Fleischmann, Roy, Henning Bliddal, Francisco J. Blanco, et al.. (2019). A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis & Rheumatology. 71(7). 1056–1069. 169 indexed citations
6.
Kloppenburg, M., Charles Peterfy, I.K. Haugen, et al.. (2018). Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Annals of the Rheumatic Diseases. 78(3). 413–420. 130 indexed citations
7.
8.
Kloppenburg, M., C. Peterfy, I.K. Haugen, et al.. (2017). OP0168 A phase 2a, placebo-controlled, randomized study of ABT-981, an anti-interleukin-1ALPHA and -1BETA dual variable domain immunoglobulin, to treat erosive hand osteoarthritis (EHOA). Annals of the Rheumatic Diseases. 76. 122–122. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ann Tamm Breakdown of academic impact, for papers by Irina Kerna Breakdown of academic impact, for papers by Brendon Richbourgh Breakdown of academic impact, for papers by Zrinka Jajić Breakdown of academic impact, for papers by A. Florescu Breakdown of academic impact, for papers by J. Ophir Breakdown of academic impact, for papers by M.A. Pest Breakdown of academic impact, for papers by Nigel K. Arden Breakdown of academic impact, for papers by Maria Rosaria Povino Breakdown of academic impact, for papers by Josef Symon S. Concha
Rankless by CCL
2026